Imipenem/cilastatin as initial therapy for febrile neutropenic patients. 1988

R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
Department of Medicine, University of Hong Kong, Queen Mary Hospital.

Imipenem 2 g daily was administered intravenously to 40 evaluable patients with neutropenia and fever. Twenty-three patients had acute leukaemia and 17 malignant lymphoma. The overall response rate was 70.0%. Of the 14 patients with documented infection, 9 (64.3%) responded. Poorer responses were observed in patients with pneumonia (40%) or pseudomonal infection (50%). The response rate was significantly higher among patients with increasing neutrophil counts during therapy (P less than 0.02). Fungal infection was a common cause of treatment failure. Gastrointestinal side effects and skin rashes were occasionally seen. No patient developed central nervous system toxicity. Imipenem is a practical alternative to antibiotic combinations for management of neutropenic infection. However, careful monitoring is essential in the subgroups of patients with pneumonia or pseudomonal infections, who may require modifications of therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D004150 Dipeptidases EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005335 Fever of Unknown Origin Fever in which the etiology cannot be ascertained. Unknown Origin Fever,Unknown Origin Fevers
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D015377 Cilastatin A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. Cilastatin Monosodium Salt,Cilastatin Sodium,MK 0791,MK-791,MK0791,MK 791,MK791,Monosodium Salt, Cilastatin,Salt, Cilastatin Monosodium,Sodium, Cilastatin

Related Publications

R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
August 1986, Antimicrobial agents and chemotherapy,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
October 1996, Journal of chemotherapy (Florence, Italy),
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
July 1999, The Korean journal of internal medicine,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
January 1996, Infection,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
March 1995, Revista medica de Chile,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
April 1992, Antimicrobial agents and chemotherapy,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
November 1988, Wiener medizinische Wochenschrift (1946),
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
April 1992, Journal of chemotherapy (Florence, Italy),
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
May 1996, The Journal of antimicrobial chemotherapy,
R Liang, and R Yung, and P Y Chau, and T K Chan, and W K Lam, and S Y So, and D Todd
April 1996, Cancer,
Copied contents to your clipboard!